13.97
-0.35 (-2.44%)
| Penutupan Terdahulu | 14.32 |
| Buka | 14.07 |
| Jumlah Dagangan | 2,579,251 |
| Purata Dagangan (3B) | 1,021,003 |
| Modal Pasaran | 1,029,095,936 |
| Harga / Jualan (P/S) | 3.81 |
| Harga / Buku (P/B) | 3.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -83.39% |
| Margin Operasi (TTM) | -85.45% |
| EPS Cair (TTM) | -2.63 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 62.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 31.15% |
| Nisbah Semasa (MRQ) | 3.45 |
| Aliran Tunai Operasi (OCF TTM) | 25.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.73 M |
| Pulangan Atas Aset (ROA TTM) | -16.27% |
| Pulangan Atas Ekuiti (ROE TTM) | -43.33% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Health Information Services (US) | Menurun | Menurun |
| Health Information Services (Global) | Menurun | Menurun | |
| Stok | Schrodinger, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.88 |
|
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations. |
|
| Sektor | Healthcare |
| Industri | Health Information Services |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.63% |
| % Dimiliki oleh Institusi | 101.76% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gates Foundation Trust | 30 Sep 2025 | 6,981,664 |
| Stephens Investment Management Group Llc | 30 Sep 2025 | 2,193,034 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (Keybanc, 78.96%) | Beli |
| Median | 24.00 (71.80%) | |
| Rendah | 18.00 (UBS, 28.85%) | Pegang |
| Purata | 22.75 (62.85%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 18.55 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Keybanc | 08 Jan 2026 | 25.00 (78.95%) | Beli | 18.61 |
| TD Cowen | 08 Jan 2026 | 24.00 (71.80%) | Beli | 18.61 |
| UBS | 07 Jan 2026 | 18.00 (28.85%) | Pegang | 18.77 |
| B of A Securities | 15 Dec 2025 | 24.00 (71.80%) | Beli | 18.21 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities |
| 09 Jan 2026 | Pengumuman | Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign |
| 17 Dec 2025 | Pengumuman | Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 09 Dec 2025 | Pengumuman | Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions |
| 06 Nov 2025 | Pengumuman | Schrödinger to Present at Jefferies London Healthcare Conference |
| 05 Nov 2025 | Pengumuman | Schrödinger Reports Third Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |